[1]. Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias.
Respiratory research [巻]25 [号]1 [頁]293 （2024年） [査読] 有
[2]. Impact of preexisting interstitial lung disease on mortality in COVID-19 patients from the early pandemic to the delta variant epidemic: a nationwide population-based study
RESPIRATORY RESEARCH [巻]25 [号]1 [頁]95 （2024年） [査読] 有
[URL] [DOI] [3]. Changes in the characteristics and outcomes of COVID-19 patients from the early pandemic to the delta variant epidemic: a nationwide population-based study.
Emerging microbes & infections [巻]12 [号]1 [頁]2155250 （2023年） [査読] 有
[DOI] [4]. Nationwide survey of adult patients with pulmonary alveolar proteinosis using the National Database of designated intractable diseases of Japan.
Respiratory investigation [巻]61 [号]3 [頁]364 -370 （2023年） [査読] 有
[DOI] [5]. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis.
BMC pulmonary medicine [巻]21 [号]1 [頁]309 （2021年） [査読] 有
[DOI]